Abstract: A method of forecasting transport of a region of plasma density enhancement within a polar region is provided. The method comprises: providing a convection model for predicting electrostatic potential distribution within the polar region over time; determining the total electron content distribution within the polar region; and determining whether reconnection is occurring. If reconnection is determined to be occurring, the method comprises: identifying a region of plasma density enhancement using the total electron content distribution; and calculating a velocity of at least a portion of the plasma density enhancement using the convection model, such that transport of a region of plasma density enhancement over time can be forecast.

Abstract: There is provided a sensor device, a sensor module, and methods for determining a position of a light source. The sensor device comprises a plurality of sensor units, each sensor unit having a respective sensor area. The sensor device also comprises a mask disposed above the plurality of sensor units and arranged such that incident light from the light source will illuminate different regions of the sensor area of each one of the sensor units depending on the position of the light source relative to the sensor device. The position of the light source may therefore be determined based on which regions of the sensor area of the sensor units are illuminated. Further, each sensor unit is arranged to be controlled by a respective unit controller to determine the position of the light source.

Abstract: Provided herein is a leukocyte tyrosine kinase (LTK) inhibitor for use in the treatment of a viral infection in a subject, wherein the viral infection is caused by an RNA virus. Also provided are methods of treating a viral infection in a subject, wherein the viral infection is caused by an RNA virus, the method comprising administering to the subject an LTK inhibitor, and the use of an LTK inhibitor in the manufacture of a medicament for the treatment of a viral infection, wherein the viral infection is caused by an RNA virus. In particular, the infection may be an influenza or coronavirus infection in a human subject.

Abstract: Provided and described herein is the use of an oligomeric protein as a binding agent for binding to lipopolysaccharide (LPS), the oligomeric protein having a coiled coil structure comprising at least two monomer peptides, wherein each monomer peptide, which may be the same or different, is capable of forming an ?-helix and comprises at least one core sequence having at least 60% sequence identity to the heptad repeat sequence of SEQ ID NO. 1. Also provide and described herein are methods of binding, detecting and removing LPS, and products comprising the oligomeric protein.

Abstract: The present invention provides a polypeptidic compound for use in prevention or treatment of cardiac remodeling in a subject, the polypeptidic compound comprising the amino acid sequence of proANP31-67, or an amino acid sequence having at least 80% sequence identity thereto.

Abstract: The invention provides compounds for use in a method of treating and/or preventing a bacterial infection in a human or non-human mammal, said method comprising administration of said compound in combination with (either simultaneously, separately, or sequentially) a ?-lactam antibiotic, wherein said compound has the general formula I: (wherein: Q is a lipophilic, zinc chelating moiety which is selective for Zn2+ ions and which comprises at least one, preferably two or more (e.g 2, 3 or 4), optionally substituted, unsaturated heterocyclic rings, e.g.

Abstract: The present invention provides a method of treating ALK-negative/LTK-positive cancer in a subject, comprising administering to the subject a pharmaceutically-effective dose of a linear inhibitor of ALK. The invention is of particular utility in treating multiple myeloma, including proteasome inhibitor-resistant multiple myeloma.

Abstract: The present disclosure provides a method and an apparatus for producing astatine-211 from alpha-particle bombardment of bismuth-209. The disclosure also relates to a method and apparatus of producing other radionuclides from target nuclides. The apparatus includes a plate having a recessed portion. The recessed portion has a generally inert surface of ceramic or metal, preferably aluminium oxide that does not react with molten bismuth. A bismuth target is placed in the recessed portion and held therein by a foil cover. The foil has a melting temperature greater than target nuclide (i.e., for bismuth, >271° C.). The foil and target nuclide are held in the recessed portion by a cover that is fastened over the foil. The cover has an aperture to allow a beam of radiation, such as alpha particles, from a cyclotron or other accelerator to pass through the cover to the foil and target nuclide.

Abstract: The invention provides compounds for use in a method of treating and/or preventing a bacterial infection in a human or non-human mammal, said method comprising administration of said compound in combination with (either simultaneously, separately, or sequentially) a ?-lactam antibiotic, wherein said compound has the general formula I: (I) (wherein: Q is a lipophilic, zinc chelating moiety which is selective for Zn2+ ions and which comprises at least one, preferably two or more (e.g 2, 3 or 4), optionally substituted, unsaturated heterocyclic rings, e.g.

Abstract: The invention generally relates to the field of saxitoxins and the identification of microorganisms capable of producing them. More specifically, the invention relates to the identification of genes encoding saxitoxin in dinoflagellates, and methods for the specific detection of dinoflagellates that are producers of saxitoxins.

Abstract: The present invention provides an inhibitor of an ADAMTS proteoglycanase for use in treating or preventing cardiac remodeling or for use in treating or preventing heart failure in a subject. In particular, the present invention provides an inhibitor of ADAMTS4 or ADAMTS5 for use in treating or preventing cardiac remodeling or chronic heart failure in a subject with cardiac remodeling or with chronic heart failure, or with a condition that may lead to cardiac remodeling and/or chronic heart failure. Also provided is a method of treating or preventing cardiac remodeling or treating or preventing heart failure which method comprises administering to a subject in need thereof a therapeutically effective amount of an inhibitor of an ADAMTS proteoglycanase. Also provided is the use of an inhibitor of an ADAMTS proteoglycanase in the manufacture of a medicament for treating or preventing cardiac remodeling or treating or preventing heart failure.

Abstract: The present invention relates to methods for assessing binding agent specificity, in particular antibody specificity. The present invention thus provides a method of analysing a mixture of polypeptides comprising the steps of: (i) separating the polypeptides in the mixture into a plurality of fractions; (ii) contacting a first aliquot of two or more of the fractions with a plurality of different binding agents attached to one or more solid supports and detecting the binding of the polypeptides to the binding agents in each fraction; (iii) assessing the amino acid composition of the polypeptides in a second aliquot of said fractions by mass spectrometry; and (iv) correlating the binding results detected in step (ii) and the mass spectrometry results from step (iii) to assess the specificity of the binding agents for a polypeptide of interest.

Abstract: There is provided a process for preparing a zirconium-based metal organic framework (Zr-MOF), the process comprising the steps (i) preparing a reaction mixture comprising zirconium ions, sulfate ions and at least one organic linker compound in an aqueous solvent; and (ii) heating the reaction mixture from step (i).

Abstract: The present invention provides an inhibitor of an ADAMTS proteoglycanase for use in treating or preventing cardiac remodeling or for use in treating or preventing heart failure in a subject. In particular, the present invention provides an inhibitor of ADAMTS4 or ADAMTS5 for use in treating or preventing cardiac remodeling or chronic heart failure in a subject with cardiac remodeling or with chronic heart failure, or with a condition that may lead to cardiac remodeling and/or chronic heart failure. Also provided is a method of treating or preventing cardiac remodeling or treating or preventing heart failure which method comprises administering to a subject in need thereof a therapeutically effective amount of an inhibitor of an ADAMTS proteoglycanase. Also provided is the use of an inhibitor of an ADAMTS proteoglycanase in the manufacture of a medicament for treating or preventing cardiac remodeling or treating or preventing heart failure.

Abstract: A self-healing ceramic ion-selective membrane assembly including a ceramic ion-selective membrane, and at least one additive layer. The at least one additive layer includes an ionic ceramic material which is porous or ion-selective. The at least one additive layer having a metal cation diffusivity higher than the metal cation diffusivity of the ceramic ion-selective membrane. When a defect occurs through the ceramic ion-selective membrane, metal cation transport will be enhanced by orders of magnitude towards and into the defect, driven by the chemical or electrical potential difference between the two sides of the membrane.

Abstract: The present invention is directed to methods of preparing biocement. The methods disclosed herein employ microbial or enzymatic means first to generate acid which dissolves CaCO3, and then to degrade urea, producing CO3? ions which increase the pH and lead to the reprecipitation of CaCO3. The precipitation of CaCO3 acts as a cementation process which can bind together particulate materials to yield mortars, concretes and suchlike. The invention further provides construction materials formed by the methods of the invention, and bacterial strains which can be used in the methods of the invention to generate organic acids.

Abstract: The present invention provides an inhibitor of an ADAMTS proteoglycanase for use in treating or preventing cardiac remodeling or for use in treating or preventing heart failure in a subject. In particular, the present invention provides an inhibitor of ADAMTS4 or ADAMTS5 for use in treating or preventing cardiac remodeling or chronic heart failure in a subject with cardiac remodeling or with chronic heart failure, or with a condition that may lead to cardiac remodeling and/or chronic heart failure. Also provided is a method of treating or preventing cardiac remodeling or treating or preventing heart failure which method comprises administering to a subject in need thereof a therapeutically effective amount of an inhibitor of an ADAMTS proteoglycanase. Also provided is the use of an inhibitor of an ADAMTS proteoglycanase in the manufacture of a medicament for treating or preventing cardiac remodeling or treating or preventing heart failure.

Abstract: The present invention relates to compositions and methods for antibody-mediated therapy. In particular, provided herein are engineered immunoglobulins with altered half-life.

Abstract: A method for the formation of lithium includes a layer on a substrate using an atomic layer deposition method. The method includes the sequential pulsing of a lithium precursor through a reaction chamber for deposition upon a substrate. Using further oxidizing pulses and or other metal containing precursor pulses, an electrolyte suitable for use in thin film batteries may be manufactured.

Abstract: A method for the formation of lithium includes a layer on a substrate using an atomic layer deposition method. The method includes the sequential pulsing of a lithium precursor through a reaction chamber for deposition upon a substrate. Using further oxidizing pulses and or other metal containing precursor pulses, an electrolyte suitable for use in thin film batteries may be manufactured.